bluuebunny/crossref_metadata_2025_split huggingface dataset:
Phonon mediated superconductivity in field-effect doped molybdenum dichalcogenides
Authors: Marini Giovanni , Calandra Matteo 
Published: November 2022

Abstract
Superconductivity occurs in electrochemically doped molybdenum dichalcogenides samples thicker than four layers. While the critical temperature (T

c
) strongly depends on the field effect geometry (single or double gate) and on the sample (MoS2 or MoSe2), T

c
always saturates at high doping. The pairing mechanism and the complicated dependence of T

c
on doping, samples and field-effect geometry are currently not understood. Previous theoretical works assumed homogeneous doping of a single layer and attributed the T

c
saturation to a charge density wave instability, however the calculated values of the electron–phonon coupling in the harmonic approximation were one order of magnitude larger than the experimental estimates based on transport data. Here, by performing fully relativistic first principles calculations accounting for the sample thickness, the field-effect geometry and anharmonicity, we rule out the occurrence of charge density waves in the experimental doping range and demonstrate a suppression of one order of magnitude in the electron–phonon coupling, now in excellent agreement with transport data. By solving the anisotropic Migdal-Eliashberg equations, we explain the behavior of T

c
in different systems and geometries. As our first principles calculations show an ever increasing T

c
as a function of doping, we suggest that extrinsic mechanisms may be responsible for the experimentally observed saturating trend.
Decoherence of a spin-valley qubit in a MoS2 quantum dot
Authors: Arfaoui Mehdi , Jaziri Sihem 
Published: November 2022

Abstract
Transition metal dichalcogenide (TMD)-based quantum dots (QDs) have proven to be a successful and promising device for physically implementing electron spin-valley based qubits. Although the electron spin in a TMDs monolayer semiconductor QD can be isolated and controlled with high precision, decoherence occurs due to unavoidable coupling with the surrounding environment, such as nuclear spin environments. In this paper, using an exact master equation (ME) of spin qubit dynamics coupled to a nuclear spin bath in terms of hyperfine interaction (HI), we have investigated the controllability of dynamics processes with varying degrees of non-Markovianity. In large magnetic fields, we show that pure spin or valley qubits can be created. We calculate the loss of fidelity due to the Overhauser field of HI in a wide range of nuclear spin

N

. In this context, we prove that this field restricts the decoherence process of the central electron spin, which can regain its coherence. Finally, we discuss how the coherence of the spin qubit remains robust for large

N

.
Utilization of bictegravir/emtricitabine/tenofovir alafenamide in patients with end-stage renal disease on hemodialysis
Authors: Sidman Eric F , Ondrush Nicole M 
Published: November 2022

Abstract

Purpose
The combination antiretroviral bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) is a single-tablet, once-daily regimen used in individuals living with HIV; however, its use in the context of renal impairment is uncertain. We report 6 patient cases of BIC/FTC/TAF utilization in individuals with HIV with end-stage renal disease (ESRD) requiring long-term hemodialysis (HD).

Summary
These case reports describe the utilization of BIC/FTC/TAF in individuals with HIV who require chronic HD, the laboratory parameters measured, and patient-reported quality of life and adverse events.

Conclusion
Utilization of BIC/FTC/TAF appears to be an option for individuals with HIV who have ESRD and require long-term HD. This regimen allows for once-daily dosing, elimination of potential serious drug interactions, and simplified patient ART regimens in our patient subset.
Application of DRGs in hospital medical record management and its impact on service quality
Authors: Zhang Qin , Li Xiaodong 
Published: November 2022

Abstract

Background
To explore the application of diagnosis-related groups (DRGs) in hospital medical record management and the impact on service quality.

Objective
This study introduced DGRs management into hospital medical record management in order to improve the quality of hospital medical record management.

Method
The medical record management of our hospital was analysed retrospectively between August 2020 and April 2021. A total of 7263 cases without DRG management before January 2021 were included in a control group, and 7922 cases with DRG management after January 2021 were included in a study group. The error rate of medical records, the specific error items and the scores of service capability, service efficiency and service quality were compared along with the comprehensive scores of the two groups.

Results
The error rate of medical records in the study group was significantly lower than that in the control group (19.35% vs. 31.24%, P &lt; 0.05). The error rates in terms of diagnosis on admission, surgical procedures, main diagnosis and other diagnoses in the study group were significantly lower than those in the control group. The scores for service ability, service efficiency and service quality were significantly higher in the study group than in the control group (P &lt; 0.05). The comprehensive evaluation score of the study group was significantly higher than that of the control group (P &lt; 0.01).

Conclusion
Applying DRGs in the hospital medical record management can effectively reduce the error rate of medical records and improve the quality of hospital services.
A Primer on Chimerism Analysis: A Straightforward, Thorough Review
Authors: Morris Anna B , Bray Robert , Gebel Howard M , Cliff Sullivan H 
Published: November 2022

Abstract
Short tandem repeat (STR) analysis to assess chimerism is a critical aspect of routine care particularly in patients facing stem cell transplants but is also relevant in other clinical scenarios. STR analysis provides a means to assess donor and recipient cellular origins in a patient, and, as such, can inform engraftment, rejection, and relapse status in stem cell transplant recipients. In this review of STR testing, the most commonly used method to assess chimerism, its background, procedural details, and clinical utility are discussed.
Likelihood ratio to evaluate handwriting evidence using similarity index
Authors: Wydra Jȩdrzej , Matuszewski Szymon 
Published: November 2022

Abstract
Previous methods to evaluate evidence from handwriting examinations were usually associated with a redefinition of how these examinations are to be made. Here we propose the likelihood ratio method for handwriting evidence evaluation which is fully compatible with the current handwriting examination protocols. The method is focused on the similarity between handwriting samples, quantified using Jaccard index from results of a usual forensic handwriting comparison. The numerator of the likelihood ratio is the probability of a given class of similarity, assuming that a given person wrote the questioned sample. The denominator is the probability of the same class of similarity, assuming that a randomly selected person wrote questioned sample. The similarity distribution to quantify the numerator is derived from comparisons across reference handwritings. To calculate the denominator we propose to develop similarity distributions relevant for particular forensic scenarios. In the proof-of-a-concept study, we developed the distribution for the simulation scenario.
ANGI-01. METASTATIC ESTHESIONEUROBLASTOMA RECURRENCE AFTER 19 YEARS OF REMISSION: A SYSTEMATIC REVIEW WITH CASE ILLUSTRATION
Authors: Mozaffari Khashayar , Pradhan Anjali , Patel Kunal , Vivas Andrew , Yang Isaac 
Published: November 2022

Abstract

INTRODUCTION
Esthesioneuroblastoma (ENB) is a rare malignant neoplasm of the olfactory epithelium with an estimated incidence of 0.4/million. It can directly extend along the cribriform plate in order to metastasize to the central nervous system. However, non-contiguous intracranial involvement without recurrence at the primary site is extremely uncommon. In this report, the authors review the literature and present a case of non-contiguous intracranial metastasis of ENB without recurrence at the primary site. To the best of our knowledge, this case presents the longest disease-free interval reported in the literature.

METHODS
A systematic review of literature was conducted in accordance with the PRISMA guidelines. Additionally, the presentation, surgical management, and post-operative outcomes of an 82-year-old female with non-contiguous intracranial metastasis of ENB after 19 years of remission are described.

RESULTS
A total of 137 deduplicated works were identified after the search. Of these, 6 papers satisfied our inclusion criteria for our systematic review. Average age at presentation was 50.8 years (range: 26-66) and 52.6% of patients were female. A majority of cases achieved gross-total resection and received adjuvant radiotherapy for initial treatment. The median interval to intracranial metastasis was 6 years from the time of primary tumor presentation. The median overall survival from ENB recurrence with non-contiguous intracranial metastasis was 12 months.

CONCLUSIONS
ENB is a highly recurrent tumor and harbors the potential to involve the intracranial space even years after remission. Intracranial involvement entails poor overall survival. Lifetime radiographic follow-up should be considered in all patients with ENB.
ANGI-08. EPIGENETIC REACTIVATION OF BAI1 SUPPRESSES TUMOR INVASION, RECURRENCE, AND SPINAL METASTASIS BY PREVENTING TGFΒ1-INDUCED MESENCHYMAL SWITCH IN GLIOBLASTOMA
Authors: Osuka Satoru , Yang Liquan , Hashimoto Hideharu , Zhu Dan , Zhang Zhaobin , Olson Jeffrey , Devi Narra , Van Meir Erwin 
Published: November 2022

Abstract
Glioblastoma (GBM) is the most common and lethal type of malignant brain tumor in adults. GBM cells spread extensively in the brain and disseminate into the cerebrospinal fluid space, strongly restricting multimodal therapies. Acquiring a better knowledge of molecular defects underlying GBM invasion is essential for developing effective treatments.Brain-specific Angiogenesis Inhibitor 1 (BAI1/ADGRB1) is a transmembrane receptor of the adhesion GPCR family widely expressed in the normal brain, but its expression is lost in the majority of GBM through epigenetic silencing and restoration of its expression can inhibit glioma growth. However, whether BAI1 loss is important for tumor invasion and the mesenchymal phenotype in GBM has not been investigated.Microarray analysis of the GBM TCGA dataset (restricted to IDHwt GBM; WHO 2021) revealed that low BAI1 mRNA expression correlates with elevated expression of many mesenchymal genes. Restoration of BAI1 expression in human GBM cells suppresses mesenchymal gene expression in culture and dramatically decreases brain tumor invasion in mice xenografts. Mechanistically, we found that the N-terminal thrombospondin type 1 repeat (TSR#1) of BAI1 inhibits the maturation process of TGFβ1, a key growth factor involved in EMT. BAI1 is silenced epigenetically in GBM cells by methylated CpG-binding protein MBD2, and its expression can be reactivated by KCC-07, a blood-brain barrier permeable MBD2 inhibitor. We found that restoration of BAI1 expression by KCC-07 treatment dramatically suppresses cell invasion in the brain and reduces leptomeningeal dissemination of GBM cells to the spine in mouse xenografts.These experiments demonstrate that epigenetic silencing of BAI1 is important for activating the GBM invasive phenotype through TGFβ1 pathway activation. This new tumor-suppressive pathway can be epigenetically targeted to reactivate BAI1 expression in GBM patients.
BIOM-02. MUTATIONAL ANALYSIS AND SINGLE CELL SEQUENCING OF MELANOMA BRAIN METASTASES REVEALS BRAF STATUS CORRELATES WITH CLINICAL OUTCOME AND DIFFERENTIAL IMMUNE POPULATIONS
Authors: Vasudevan Harish , Delley Cyrille , Aabedi Alexander , Shukla Poojan , Nguyen Minh , Morshed Ramin A , Young Jacob S , Demaree Ben , Diwanji Devan , Hervey-Jumper Shawn L , Boreta Lauren , Fogh Shannon , Nakamura Jean , Theodospoulos Philip , Phillips Joanna J , Daras Mariza , Tsai Katy , Sneed Penny , Aghi Manish , Raleigh David , Braunstein Steve , Abate Adam 
Published: November 2022

Abstract
Understanding the molecular landscape and microenvironment of melanoma brain metastases is critical to devise improved treatments. Here, we perform bulk and single cell genomic analysis of melanoma brain metastases to identify molecular correlates of clinical outcome. 84 consecutive patients who underwent surgical resection at a single institution with a histo-pathologically confirmed diagnosis of melanoma brain metastasis were retrospectively identified. In 60 patients (71%) with sufficient brain metastasis tissue for targeted next generation sequencing, DNA mutations were assessed with a CLIA certified sequencing assay. Single nuclear RNA sequencing using the 10x platform was performed on n=6 samples from treatment naïve patients. Overall survival (OS) and CNS progression free survival (CNS PFS) from time of brain metastasis diagnosis were estimated using the Kaplan-Meier method. The median patient age was 62 years old (range: 25-78 years), and the median clinical follow up was 17 months. A total of 33 patients (39%) had BRAFV600E melanoma brain metastases. Multivariate analysis incorporating age, performance status, and extracranial disease revealed BRAF status was an independent prognostic factor for OS (p&lt; 0.05). In patients undergoing targeted next generation sequencing, the most common pathogenic variant was TERT promoter mutation (n=44; 73%). With regard to TCGA molecular melanoma subgroups, NRAS mutant (n=22; 37%) brain metastases were most common followed by BRAF mutant (n=20; 33%), NF1 mutant (n=11; 18%), and triple wildtype (n=7; 12%). Evaluation of clinical outcomes in the context of next generation sequencing results revealed no differences by TERT status but demonstrated worse overall survival in the BRAF mutant molecular group (p&lt; 0.01, log-rank test). Single nuclear sequencing of 36,115 nuclei across 6 samples revealed BRAF wildtype tumors exhibit greater infiltrating immune cell populations including microglia and T cell subtypes. Future work will require integration of these findings with different systemic therapy regimens and across larger, prospective, multi-institutional cohorts.
BIOM-13. MICROPERFUSION-MEDIATED SOLUBLE EXTRACELLULAR ENVIRONMENT ANALYSIS FOR DETERMINATION OF CHEMOTHERAPEUTIC EFFICACY IN BRAIN TUMORS
Authors: Olson Ian , Zolp Andrew , Ventarapragada Divya , Miska Jason , Ahmed Atique 
Published: November 2022

Abstract
Glioblastoma (GBM) is the most prevalent and lethally recurrent central nervous system neoplasm, but its therapeutic advancement has stagnated for over 15 years. One major hurdle in front of clinical breakthroughs has been the relative lack of real-time, treatment-responsive biomarkers that occur during therapy. The methods of microdialysis and microperfusion, now entering both clinical and pre-clinical settings, offers an opportunity to overcome this hurdle by providing real-time, biologically relevant monitoring of the tumor microenvironment (TME). The goal of this project is to identify changes in the soluble extra-cellular regional environment of the tumor (SECRETome) of GBM in response to standard-of-care treatments using intra-tumoral microperfusion. In this study, we evaluated the response of murine GBM tumors to temozolomide (TMZ) during therapy by combining transcriptional changes to metabolic phenotypes obtained from SECRETome analysis. Our data demonstrated a 2-fold increase in levels of microperfusion-sampled 2-hydroxyglutarate (2-HG) on day 3 post-TMZ therapy as compared to untreated tumors. This expression is correlated with our RNAseq analysis wherein we observed an &gt;600 fold increase in malate dehydrogenase 1 (MDH1 - an enzyme that converts alpha-ketoglutarate to 2-HG) on Day 4 post-TMZ treatment (p = 4.20e-04) as compared to untreated tumors. Therefore, we found that interstitial elevation of a TMZ-associated metabolite can be used to probe the genetic changes that occur within GBM during therapy. This proof-of-concept study demonstrates that microperfusion-mediated TME sampling can be used to understand the complex biological responses process that occurs during GBM chemotherapy, and may provide unique insights into how to better treat these tumors in the future. Moreover, the future establishment of clinical intra-operative microdialysis/microperfusion can be extrapolated to improve the pace of clinical therapeutic translation through homologous, treatment-responsive biomarkers in humans.
BIOM-16. A MULTI-OMIC, FUNCTIONAL PRECISION ONCOLOGY METHOD TO IDENTIFY RESPONSIVE GLIOBLASTOMA TUMOR CELLS AT SINGLE CELL RESOLUTION
Authors: De Visser Yanti , Panovska Dena , Cole Basiel , Hermans Lotte , Martinez Asier Antoranz , Nazari Pouya , Van Trimpont Maaike , Derweduwe Marleen , Claeys Annelies , De Vleeschouwer Steven , Solie Lien , Clement Paul , Sciot Raf , Verfaillie Michiel , Daenekindt Thomas , Bamps Sven , Van Vlierberghe Pieter , De Smet Frederik 
Published: November 2022

Abstract
Glioblastoma remains a highly malignant and intrinsically resistant brain tumor. Despite intensive research through which numerous potential druggable targets were identified, virtually all clinical trials of the past 20 years failed to improve the outcome for the vast majority of GBM patients. However, the identification of small subgroups of patients that showed an exceptional response across several trials, implies that, when selected more carefully, some GBM patients could probably still benefit from these therapies. Identifying these patients requires that suitable biomarkers are identified. In this project, we reassessed the molecular mechanisms of ten actionable compounds (selected from previously failed trials but for which exceptional responders had been observed) in a set of carefully selected patient-derived cell lines that were sensitive/resistant to the selected therapies. Moreover, to deal with tumor heterogeneity, we used a multi-omic functional precision oncology approach, combining scRNA-seq and CyTOF, to identify drug-specific biomarkers by comparing control and treated samples at single-cell resolution. By subsequently correlating the molecular signatures to eventual cytotoxicity profiles, we could identify intrinsically responsive tumor cells at the single-cell level within hours following drug exposure. Overall, this work lays the foundation for an actionable functional diagnostic assay that could help to identify eligible GBM patients in future clinical trials.
BIOM-17. SPYING ON GLIOMAS: LONGITUDINAL CSF AS A PLATFORM FOR GLIOMA MONITORING AND RESPONSE BIOMARKER DISCOVERY
Authors: Riviere-Cazaux Cecile , Ikram Samar , Chantigian Siobhan , Rahman Masum , Warrington Arthur , Burns Terry 
Published: November 2022

Abstract
The relative inaccessibility of a patient’s glioma throughout their disease course precludes individualized insights into tumor biology and responses thereof to therapeutic challenge. We propose that serial cerebrospinal fluid (CSF) samples can be used to perform glioma espionage in the form of biomarker discovery for analytes that are sensitive to tumor burden (for monitoring) and candidate therapies (for biological impact). To that end, we are routinely leveraging neurosurgical access to the CNS to collect CSF samples intraoperatively and from chronically implanted Ommaya reservoirs for longitudinal CSF access (NCT04692337, NCT04692324). Global proteomic analysis of CSF was performed on the Somalogic platform – an aptamer-based technology for highly sensitive and specific analysis of over 7,000 proteins. Using each patient’s ranked protein list (glioma vs. 3 control patients), enrichment analysis was performed in a discovery cohort of five patients to identify conserved proteins of glioma. To reveal candidate glioma monitoring, further enrichment analysis was performed to identify proteins that decreased with resection and increased with recurrence, using two sets of paired patient samples. Forty-four proteins met these enrichment criteria; this candidate high-grade glioma proteomic signature was highly significantly enriched in an independent cohort of twelve glioma patients (FDR=0 for all patients). The HGG signature decreased in abundance following resection in serial samples from two other patients, confirming decreased tumor burden. Top proteins included LANC2, DPYL3, Sorcin, Integrin A1B1, and lactate dehydrogenase (FC of glioma vs. control: 145.3x, 113.9x, 78.0x, 71.6x, and 62.7x, respectively). Interestingly, despite having explicitly chosen samples with little-to-no hemoglobin in the discovery cohort, this HGG signature was highly enriched for plasma-like proteins (FDR=0), suggesting a potential biological impact of blood-brain barrier disruption on the glioma extracellular proteome. In conclusion, our data demonstrate that the glioma extracellular proteome can feasibly be accessed to perform biomarker discovery (“espionage”) via serially-acquired CSF samples.
BIOM-18. CLINICOGENOMIC PREDICTORS FOR THE PATTERN OF FAILURE IN HIGH-GRADE GLIOMA
Authors: Kang Byung-Hee , Ho Lee Joo , Kim Tae Min , Yun Hongseok , Won Jae-Kyung , Choi Seung Hong , Lee Soon-Tae , Park Sung-Hye , Park Chul-Kee 
Published: November 2022

Abstract

Background
High-grade gliomas, the most common primary brain tumors, are highly lethal and treatment options remain limited. Despite advances in genomic technologies, there are few molecular biomarkers to guide precision medicine for high-grade glioma. Here, we aimed to identify the clinicogenomic features associated with its prognosis and recurrence patterns.

MATERIALS/METHODS
Our single-institution retrospective analysis included 182 patients diagnosed with high-grade gliomas who underwent next-generation sequencing targeting 82 brain tumor-relevant genes. Clinicopathological status, treatment characteristics, survival, and genomic profiles were analyzed.

RESULTS
At a median follow-up of 23 months (range, 2-229 months), 151 patients (83%) had progression or recurrences. Local and distant recurrences were observed in 132 (72.5%) and 101 (54.9%) patients, respectively. The most common genomic variants in high-grade gliomas were TP53 (42.9%), IDH1/2 (23.1%), TERT promoter (38.5%), ATRX (13.2%), H3F3A (7.1%), and SETD2 (6.0%) mutation. Regarding copy number variants, amplification of EGFR (20.9%), PDGFRA (9.9%), MYCN (2.2%) and loss of CDKN2A/2B (49.5%), PTEN (37.9%), RB1 (17.6%), and 1p19q codeletion(9.3%) were the most common copy number aberrations. On multivariate cox regression anlalysis, MYCN amplification (HR 6.08 95% CI 1.91-19.35, p = 0.002), and SETD2 mutation (HR 0.19 95% CI 0.06-0.62, p =0.06) were independent predictors of overall survival, in relation to previously established prognostic factors including age, Eastern Cooperative Oncology Group Performance Status (ECOG PS) scale, extent of resection, MGMT promoter methylation, and IDH1/2 mutation. Interestingly, MYCN amplification (HR 5.24 95% CI 1.69-16.27, p = 0.004), SETD2 mutation (HR 0.35 95% CI 0.12-0.99, p =0.048) were independent predictors of failure from distant recurrences.

CONCLUSION
The assessment of genomic characteristics in conjunction with pattern of failure for high-grade glioma aids to identify patients who are likely to benefit from personalized medicine. We identified SETD2 mutation, and MYCN as a prognostic biomarkers with potential therapeutic implications in patients with high-grade glioma.